Literature DB >> 10320641

Regulation of complement factor H in a human liver cell line by interferon-gamma.

W Luo1, D P Vik.   

Abstract

Factor H is a regulatory protein of the alternative pathway of complement activation. The liver is the major site of synthesis. We have used the Hep3b human liver cell line as a model for examining its regulation by interferon-gamma (IFN-gamma). The maximal response was achieved at 50 U/ml of IFN-gamma. An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX. Phosphorylation events were also important in this induction because the kinase inhibitors staurosporine and genistein inhibited the induction of H mRNA by 88% and 68%, respectively. The induction could be inhibited completely when Hep3b cells were treated with CHX and staurosporine. Thus induction of factor H by IFN-gamma apparently involves two factors. One is likely to be Stat1alpha and the other is a CHX-sensitive protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10320641     DOI: 10.1046/j.1365-3083.1999.00528.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  Enhanced expression of the complement factor H mRNA in proliferating human RPE cells.

Authors:  Norbert Kociok; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-08       Impact factor: 3.117

2.  Complement factor H gene (CFH) polymorphisms C-257T, G257A and haplotypes are associated with protection against severe dengue phenotype, possible related with high CFH expression.

Authors:  André F Pastor; Laís Rodrigues Moura; José W D Neto; Eduardo J M Nascimento; Carlos E Calzavara-Silva; Ana Lisa V Gomes; Ana Maria da Silva; Marli T Cordeiro; Ulisses Braga-Neto; Sergio Crovella; Laura H V G Gil; Ernesto T A Marques; Bartolomeu Acioli-Santos
Journal:  Hum Immunol       Date:  2013-06-06       Impact factor: 2.850

3.  Human adrenomedullin and its binding protein ameliorate sepsis-induced organ injury and mortality in jaundiced rats.

Authors:  Juntao Yang; Rongqian Wu; Mian Zhou; Ping Wang
Journal:  Peptides       Date:  2010-02-02       Impact factor: 3.750

4.  Human adrenomedullin and its binding protein attenuate organ injury and reduce mortality after hepatic ischemia-reperfusion.

Authors:  Juntao Yang; Rongqian Wu; Xiaoling Qiang; Mian Zhou; Weifeng Dong; Youxin Ji; Corrado P Marini; Thanjavur S Ravikumar; Ping Wang
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

5.  Human vasoactive hormone adrenomedullin and its binding protein rescue experimental animals from shock.

Authors:  Rongqian Wu; Weifeng Dong; Xiaoling Qiang; Youxin Ji; Tianpen Cui; Juntao Yang; Mian Zhou; Steven Blau; Corrado P Marini; Thanjavur S Ravikumar; Ping Wang
Journal:  Peptides       Date:  2008-03-08       Impact factor: 3.750

6.  Adrenomedullin and adrenomedullin binding protein-1 protect endothelium-dependent vascular relaxation in sepsis.

Authors:  Mian Zhou; Subir R Maitra; Ping Wang
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

7.  Reversing established sepsis in rats with human vasoactive hormone adrenomedullin and its binding protein.

Authors:  Rongqian Wu; Shinya Higuchi; Weifeng Dong; Youxin Ji; Mian Zhou; Corrado P Marini; Thanjavur S Ravikumar; Ping Wang
Journal:  Mol Med       Date:  2008-10-10       Impact factor: 6.354

8.  Podocytes Produce and Secrete Functional Complement C3 and Complement Factor H.

Authors:  Anne K Mühlig; Lindsay S Keir; Jana C Abt; Hannah S Heidelbach; Rachel Horton; Gavin I Welsh; Catherine Meyer-Schwesinger; Christoph Licht; Richard J Coward; Lars Fester; Moin A Saleem; Jun Oh
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.